PT  - JOURNAL ARTICLE
AU  - Jutta Beier
AU  - Anne-Marie Kirsten
AU  - Robert Mróz
AU  - Rosa Segarra
AU  - Ferran Chuecos
AU  - Cynthia Caracta
AU  - Esther Garcia Gil
TI  - Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - 184
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/184.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/184.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Background: The efficacy and safety of aclidinium bromide vs tiotropium and placebo in COPD has been evaluated in a randomized, double-blind, Phase IIIb study.Aim: To report additional endpoints capturing the effect of treatment on COPD daily symptoms.Methods: 414 patients with COPD (FEV1 1.6 L; 56% predicted) received aclidinium bromide 400 µg BID (metered dose; equivalent to aclidinium 322 µg delivered dose), tiotropium 18 µg QD or placebo for 6 weeks. Symptoms were assessed daily with the EXACT-Respiratory Symptoms (E-RS) and COPD additional symptoms questionnaires. Relief medication use was assessed.Results: Results are summarized (Table).View this table:Change from baseline (difference vs placebo) over 6 weeksConclusions: Aclidinium provides significant COPD daily symptom improvement vs placebo, including less severe early-morning and night-time symptoms, and a greater number of relief medication-free days. Improvements were consistently numerically greater with aclidinium vs tiotropium.